Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 151 to 200 of 383

TitleTypeExpected publication date
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373Technology appraisal guidanceTBC
Implanting a baroreceptor stimulation device for resistant hypertensionInterventional procedures guidanceTBC
Indoor air quality at homeQuality standardTBC
Infection prevention and control updateQuality standardTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Insertion of neo-chordae into the beating heart for mitral regurgitationInterventional procedures guidanceTBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Technology appraisal guidance
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981Technology appraisal guidanceTBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]Technology appraisal guidance
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]Technology appraisal guidanceTBC
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Kidney CancerNICE guidelineTBC
Kidney CancerQuality standardTBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]Technology appraisal guidanceTBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidanceTBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]Highly specialised technology
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]Technology appraisal guidanceTBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Technology appraisal guidanceTBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]Technology appraisal guidanceTBC
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]Technology appraisal guidanceTBC
Linzagolix for treating pain caused by endometriosis [ID6357]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]Technology appraisal guidance
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lymphoedema: prevention and management in people with early, locally advanced, and advanced breast cancer (update)NICE guidelineTBC
Managing common infections - antimicrobial prescribing guidelinesNICE guidelineTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]Technology appraisal guidanceTBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257Technology appraisal guidanceTBC
Maternal and child nutritionNICE guideline
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Meningitis (bacterial) and meningococcal disease updateQuality standard
Menopause: diagnosis and managementNICE guidelineTBC
Mental health guidelinesNICE guidelineTBC
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Technology appraisal guidance
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All